Proteomic contributions to personalized cancer care.
Cancer impacts each patient and family differently. Our current understanding of the disease is primarily limited to clinical hallmarks of cancer, but many specific molecular mechanisms remain elusive. Genetic markers can be used to determine predisposition to tumor development, but molecularly targeted treatment strategies that improve patient prognosis are not widely available for most cancers. Individualized care plans, also described as personalized medicine, still must be developed by understanding and implementing basic science research into clinical treatment. Proteomics holds great promise in contributing to the prevention and cure of cancer because it provides unique tools for discovery of biomarkers and therapeutic targets. As such, proteomics can help translate basic science discoveries into the clinical practice of personalized medicine. Here we describe how biological mass spectrometry and proteome analysis interact with other major patient care and research initiatives and present vignettes illustrating efforts in discovery of diagnostic biomarkers for ovarian cancer, development of treatment strategies in lung cancer, and monitoring prognosis and relapse in multiple myeloma patients.
Koomen
John M
JM
H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA. john.koomen@moffitt.org
Haura
Eric B
EB
Bepler
Gerold
G
Sutphen
Rebecca
R
Remily-Wood
Elizabeth R
ER
Benson
Kaaron
K
Hussein
Mohamad
M
Hazlehurst
Lori A
LA
Yeatman
Timothy J
TJ
Hildreth
Lynne T
LT
Sellers
Thomas A
TA
Jacobsen
Paul B
PB
Fenstermacher
David A
DA
Dalton
William S
WS
D014408:Biomarkers, Tumor / Q000032:analysis; D006801:Humans; D013058:Mass Spectrometry; D009363:Neoplasm Proteins / Q000032:analysis; D009369:Neoplasms / Q000175:diagnosis / Q000201:enzymology / Q000378:metabolism / Q000628:therapy*; D040901:Proteomics; D015398:Signal Transduction
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins